4.6 Article

Icariin attenuates the tumor growth by targeting miR-1-3p/TNKS2/Wnt/β-catenin signaling axis in ovarian cancer

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Review Obstetrics & Gynecology

The Role of miRNA in Ovarian Cancer: an Overview

Lihui Zhao et al.

Summary: This article summarizes the current studies on microRNAs (miRNAs) in ovarian cancer (OC) and introduces the latest updates on miRNAs in early screening, treatment, and prognostic prediction of OC, demonstrating their clinical significance. miRNAs play an important role in the progression of OC and their dysregulation can serve as biomarkers for diagnosis, treatment, and prognosis.

REPRODUCTIVE SCIENCES (2022)

Review Chemistry, Medicinal

Tankyrase inhibitors: emerging and promising therapeutics for cancer treatment

Anu Verma et al.

Summary: Cancer is characterized by uncontrolled cell growth and tankyrase has emerged as a potential target for therapy. Inhibition of tankyrase is being explored as a strategy for discovering novel anticancer drugs. Research on new lead structures as tankyrase inhibitors is ongoing, focusing on structure-activity relationships and binding modes.

MEDICINAL CHEMISTRY RESEARCH (2021)

Article Pharmacology & Pharmacy

Optimized Icariin Cubosomes Exhibit Augmented Cytotoxicity against SKOV-3 Ovarian Cancer Cells

Usama A. Fahmy et al.

Summary: The optimized ICA-loaded cubosomes showed enhanced cytotoxicity and apoptotic potential against ovarian cancer cell lines, with improved solubility and cellular permeability compared to free ICA, indicating a prospective approach for better control of ovarian cancer growth.

PHARMACEUTICS (2021)

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Article Oncology

Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial

Susana Banerjee et al.

Summary: The study demonstrated that maintenance therapy with olaparib for 2 years can extend progression-free survival to over 4.5 years in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation. These results support the use of maintenance olaparib as a standard of care in this setting.

LANCET ONCOLOGY (2021)

Article Oncology

Ovarian Cancer, Version 2.2020

Deborah K. Armstrong et al.

Summary: Epithelial ovarian cancer is a leading cause of gynecologic cancer death in the United States. The NCCN Guidelines discuss various ovarian cancers, focusing on primary treatment aspects and including recommendations for both common and rare subtypes.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)

Article Biochemistry & Molecular Biology

LINC00242/miR-1-3p/G6PD axis regulates Warburg effect and affects gastric cancer proliferation and apoptosis

Peng Deng et al.

Summary: Reprogrammed glucose metabolism and aerobic glycolysis are hallmarks of cancer, with lncRNA LINC00242 being identified as a stimulative factor in gastric cancer progression by positively regulating G6PD through miR-1-3p. Silencing LINC00242 or G6PD inhibits cell proliferation and glycolysis in vitro and relieves tumorigenesis in vivo. MiR-1-3p directly targets LINC00242 and G6PD, and overexpression of miR-1-3p suppresses gastric cancer cell proliferation and glycolysis.

MOLECULAR MEDICINE (2021)

Review Biotechnology & Applied Microbiology

Natural products in drug discovery: advances and opportunities

Atanas G. Atanasov et al.

Summary: Natural products and their analogues have historically played a significant role in pharmacotherapy, however, they also present challenges. Recent technological and scientific developments are addressing these challenges and revitalizing interest in natural products as drug leads, particularly for combating antimicrobial resistance.

NATURE REVIEWS DRUG DISCOVERY (2021)

Article Chemistry, Multidisciplinary

Green Synthesis of Silver Nanoparticles Using Annona muricata Extract as an Inducer of Apoptosis in Cancer Cells and Inhibitor for NLRP3 Inflammasome via Enhanced Autophagy

Majid S. Jabir et al.

Summary: This study demonstrates that silver nanoparticles prepared using Annona muricata peel extract exhibit anti-proliferative activity against leukemia cell lines, while also significantly increasing autophagy and reducing levels of IL-1 beta and NLRP3. This suggests that AgNPs could be a potent therapy for various types of cancer and an alternative treatment for preventing inflammation by enhancing autophagy.

NANOMATERIALS (2021)

Article Pharmacology & Pharmacy

Icariin regulates miR-23a-3p-mediated osteogenic differentiation of BMSCs via BMP-2/Smad5/Runx2 and WNT/β-catenin pathways in osteonecrosis of the femoral head

Xiao-yun Zhang et al.

Summary: Icariin promotes BMSC viability and osteogenic differentiation by reducing miR-23a-3p levels and regulating the BMP-2/Smad5/Runx2 and WNT/8-catenin pathways, ultimately improving osteonecrosis of the femoral head.

SAUDI PHARMACEUTICAL JOURNAL (2021)

Article Oncology

Influence of icariin on inflammation, apoptosis, invasion, and tumor immunity in cervical cancer by reducing the TLR4/MyD88/NF-κB and Wnt/β-catenin pathways

Chunyang Li et al.

Summary: In summary, ICA demonstrates significant anti-tumor effects in both in vivo and in vitro settings by inhibiting tumor growth and enhancing immune responses. It also regulates inflammatory pathways and promotes apoptosis through modulating specific signaling pathways. This suggests that ICA could potentially serve as a supplementary agent for cervical cancer treatment.

CANCER CELL INTERNATIONAL (2021)

Article Oncology

First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors

Michael L. Maitland et al.

Summary: The PTK7-targeted ADC PF-06647020 demonstrated therapeutic activity in previously treated patients with ovarian cancer, NSCLC, and TNBC, with an overall objective response rates of 27%, 19%, and 21% respectively. The recommended phase II dose was 2.8 mg/kg every 3 weeks, supporting further clinical evaluation for patients with advanced malignancies to optimize dose, schedule, and predictive tissue biomarker testing.

CLINICAL CANCER RESEARCH (2021)

Article Medicine, Research & Experimental

Icariin inhibits oral squamous cell carcinoma cell proliferation and induces apoptosis via inhibiting the NF-κB and PI3K/AKT pathways

Ling Sun et al.

Summary: Icariin can inhibit the proliferation of OSCC cells and induce apoptosis by inhibiting the NF-kappa B and PI3K/AKT signaling pathways.

EXPERIMENTAL AND THERAPEUTIC MEDICINE (2021)

Review Chemistry, Medicinal

Natural Products in Cancer Therapy: Past, Present and Future

Min Huang et al.

Summary: Natural products have been extensively studied for their anticancer potential for over half a century, leading to significant advancements in clinical use and therapeutic opportunities. However, challenges remain as the landscape of cancer therapy evolves and cutting-edge technologies play an increasing role. It is crucial to revisit and explore strategies for understanding and utilizing natural products in cancer therapy.

NATURAL PRODUCTS AND BIOPROSPECTING (2021)

Article Biochemistry & Molecular Biology

miRDB: an online database for prediction of functional microRNA targets

Yuhao Chen et al.

NUCLEIC ACIDS RESEARCH (2020)

Article Oncology

Cancer statistics, 2020

Rebecca L. Siegel et al.

CA-A CANCER JOURNAL FOR CLINICIANS (2020)

Review Biochemistry & Molecular Biology

Wnt signaling in cancer: therapeutic targeting of Wnt signaling beyond β-catenin and the destruction complex

Youn-Sang Jung et al.

EXPERIMENTAL AND MOLECULAR MEDICINE (2020)

Review Pharmacology & Pharmacy

Targeting β-Catenin Signaling by Natural Products for Cancer Prevention and Therapy

Wen-Kai Yu et al.

FRONTIERS IN PHARMACOLOGY (2020)

Review Medicine, Research & Experimental

Targeting miRNAs by natural products: A new way for cancer therapy

Beilei Zhang et al.

BIOMEDICINE & PHARMACOTHERAPY (2020)

Review Biochemistry & Molecular Biology

Casein Kinase 1α as a Regulator of Wnt-Driven Cancer

Chen Shen et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)

Review Medicine, Research & Experimental

miR-1: A comprehensive review of its role in normal development and diverse disorders

Amin Safa et al.

BIOMEDICINE & PHARMACOTHERAPY (2020)

Article Multidisciplinary Sciences

The epigenetic regulator Mll1 is required for Wnt-driven intestinal tumorigenesis and cancer stemness

Johanna Grinat et al.

NATURE COMMUNICATIONS (2020)

Article Oncology

Inhibition of the Wnt/beta-catenin pathway enhances antitumor immunity in ovarian cancer

David W. Doo et al.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)

Review Cell Biology

Regulation of microRNA function in animals

Luca F. R. Gebert et al.

NATURE REVIEWS MOLECULAR CELL BIOLOGY (2019)

Article Biotechnology & Applied Microbiology

Tankyrase Promotes Aerobic Glycolysis and Proliferation of Ovarian Cancer through Activation of Wnt/-Catenin Signaling

Hong-Yi Yang et al.

BIOMED RESEARCH INTERNATIONAL (2019)

Review Environmental Sciences

MicroRNA in Ovarian Cancer: Biology, Pathogenesis, and Therapeutic Opportunities

San-Nung Chen et al.

INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2019)

Review Reproductive Biology

Wnt/β-catenin signalling in ovarian cancer: Insights into its hyperactivation and function in tumorigenesis

Vu Hong Loan Nguyen et al.

JOURNAL OF OVARIAN RESEARCH (2019)

Article Pharmacology & Pharmacy

Anti-myeloma Effects of Icariin Are Mediated Through the Attenuation of JAK/STAT3-Dependent Signaling Cascade

Young Yun Jung et al.

FRONTIERS IN PHARMACOLOGY (2018)

Article Oncology

The putative tumour suppressor miR-1-3p modulates prostate cancer cell aggressiveness by repressing E2F5 and PFTK1

Sen-Mao Li et al.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2018)

Review Pharmacology & Pharmacy

Regulation of Wnt/β-catenin signalling by tankyrase-dependent poly(ADP-ribosyl) ation and scaffolding

Laura Mariotti et al.

BRITISH JOURNAL OF PHARMACOLOGY (2017)

Article Oncology

DDB2 Is a Novel Regulator of Wnt Signaling in Colon Cancer

Shuo Huang et al.

CANCER RESEARCH (2017)

Article Oncology

WNT Signaling and Colorectal Cancer

Emma M. Schatoff et al.

CURRENT COLORECTAL CANCER REPORTS (2017)

Article Medicine, Research & Experimental

Targeting the Wnt/β-catenin pathway in primary ovarian cancer with the porcupine inhibitor WNT974

Jonathan D. Boone et al.

LABORATORY INVESTIGATION (2016)

Article Oncology

Anti-angiogenic agents in ovarian cancer: past, present, and future

B. J. Monk et al.

ANNALS OF ONCOLOGY (2016)

Article Oncology

Wnt Signaling and Survival of Women With High-Grade Serous Ovarian Cancer A Brief Report

Brandon-Luke L. Seagle et al.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2016)

Review Pharmacology & Pharmacy

Anti-Cancer Properties of the Naturally Occurring Aphrodisiacs: Icariin and Its Derivatives

Hui-Li Tan et al.

FRONTIERS IN PHARMACOLOGY (2016)

Article Oncology

Augmentation of Response to Chemotherapy by microRNA-506 Through Regulation of RAD51 in Serous Ovarian Cancers

Guoyan Liu et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)

Article Oncology

Augmentation of Response to Chemotherapy by microRNA-506 Through Regulation of RAD51 in Serous Ovarian Cancers

Guoyan Liu et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)

Review Oncology

MicroRNA biogenesis pathways in cancer

Shuibin Lin et al.

NATURE REVIEWS CANCER (2015)

Article Pharmacology & Pharmacy

Tankyrases: Structure, Function and Therapeutic Implications in Cancer

Teemu Haikarainen et al.

CURRENT PHARMACEUTICAL DESIGN (2014)

Editorial Material Gastroenterology & Hepatology

WNT/β-Catenin Signaling and Hepatocellular Carcinoma

Jack R. Wands et al.

HEPATOLOGY (2014)

Article Chemistry, Multidisciplinary

Icariin potentiates the antitumor activity of gemcitabine in gallbladder cancer by suppressing NF-κB

Dian-cai Zhang et al.

ACTA PHARMACOLOGICA SINICA (2013)

Review Oncology

The Wnt/β-catenin pathway in ovarian cancer: A review

Rebecca C. Arend et al.

GYNECOLOGIC ONCOLOGY (2013)

Article Oncology

Therapeutic Synergy between microRNA and siRNA in Ovarian Cancer Treatment

Masato Nishimura et al.

CANCER DISCOVERY (2013)

Article Oncology

MiR-182 overexpression in tumourigenesis of high-grade serous ovarian carcinoma

Zhaojian Liu et al.

JOURNAL OF PATHOLOGY (2012)

Article Oncology

Growth Inhibition of Ovarian Tumor-Initiating Cells by Niclosamide

Yi-Te Yo et al.

MOLECULAR CANCER THERAPEUTICS (2012)

Review Biotechnology & Applied Microbiology

Tankyrase-targeted therapeutics: expanding opportunities in the PARP family

Jenna L. Riffell et al.

NATURE REVIEWS DRUG DISCOVERY (2012)

Article Oncology

MiR-15a and MiR-16 Control Bmi-1 Expression in Ovarian Cancer

Resham Bhattacharya et al.

CANCER RESEARCH (2009)

Review Cell Biology

Wnt/β-Catenin Signaling: Components, Mechanisms, and Diseases

Bryan T. MacDonald et al.

DEVELOPMENTAL CELL (2009)

Article Multidisciplinary Sciences

Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling

Shih-Min A. Huang et al.

NATURE (2009)